Alloy Therapeutics, a biotechnology company focused on drug discovery, has entered into a strategic collaboration and license agreement with Takeda Pharmaceutical to develop Takeda’s proprietary induced pluripotent stem cell (iPSC) derived CAR-T cell platform (iCAR-T) and iPSC-derived CAR-NK platform (iCAR-NK).
 
“This agreement between Takeda and Alloy aims to advance iCAR-T from discovery to clinical development,” said Yasushi Kajii, Head of R&D Japan Region at Takeda. “We look forward to seeing iCAR-T and iCAR-NK blossom as the technology advances to its next phase.”
 
“We are honored and excited to be chosen by Takeda to collaborate in fulfilling the promise of iPSC,” said Errik Anderson, Founder, Chairman & CEO of Alloy. “This is another instance of how Alloy’s flexible approach allows us to enable the global scientific community with cutting edge technologies designed for rapid, successful drug development. We believe a robust engagement with the ecosystem will play a critical role in unlocking the vast potential of iPSC and enabling the next generation of cancer therapeutics.”
 
Under the agreement, Alloy will gain co-exclusive rights to commercialize iCAR-T and iCAR-NK products for oncology indications. The company will leverage its unique business model to advance the platform and enable broader access for biotech and pharma partners.
 
Also, to support these efforts, Alloy is establishing a Japanese subsidiary to focus on cell therapy development.